<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04156685</url>
  </required_header>
  <id_info>
    <org_study_id>A84_07BE1908</org_study_id>
    <nct_id>NCT04156685</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Safety and Tolerability of CKD-387 10/500mg BE Phase1</brief_title>
  <official_title>An Open-label, Rendomized, Single-dose Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-387 in Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of&#xD;
      CKD-387&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label, randomized, single-dose crossover study to evaluate the pharmacokinetics,&#xD;
      safety and tolerability of CKD-387 in helalthy subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 6, 2019</start_date>
  <completion_date type="Actual">October 2, 2019</completion_date>
  <primary_completion_date type="Actual">August 30, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>2 part, 2x2 crossover study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A : Cmax under fasting condition</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Maximum concentration of the dapagliflozin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A : Cmax under fasting condition</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Maximum concentration of the metformin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A : AUClast under fasting condition</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Area Under Curve(last) of the dapagliflozin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A : AUClast under fasting condition</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Area Under Curve(last) of the metformin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B : Cmax under fed condition</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Maximum concentration of the metformin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B : AUClast under fed condition</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Area Under Curve(last) of the metformin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A : AUCinf under fasting condition</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Area Under Curve(infinit) of the dapagliflozin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A : AUCinf under fasting condition</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Area Under Curve(infinit) of the metformin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A : Tmax under fasting condition</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Time of maximum concentration of the dapagliflozin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A : Tmax under fasting condition</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Time of maximum concentration of the metformin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A : t1/2 under fasting condition</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Half life of the dapagliflozin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A : t1/2 under fasting condition</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Half life of the metformin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B : AUCinf under fed condition</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Area Under Curve(infinit) of the metformin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B : Tmax under fed condition</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Time of Maximum concentration of the metformin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B : t1/2 under fed condition</measure>
    <time_frame>0(predose)~48 hours</time_frame>
    <description>Half life of the metformin</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Type2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>PartA, Treatment-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 : Reference drug Period 2 : Test drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PartA, Treatment-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 : Test drug Period 2 : Reference drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PartB, Treatment-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 : Reference drug Period 2 : Test drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PartB, Treatment-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 : Test drug Period 2 : Reference drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part A, Reference (D635 10/500mg, Astrazeneca)</intervention_name>
    <description>Once a day. Under fasting condition</description>
    <arm_group_label>PartA, Treatment-1</arm_group_label>
    <other_name>PartA, Test(CKD-387 10/500mg)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part A, Reference (D635 10/500mg, Astrazeneca)</intervention_name>
    <description>Once a day. Under fasting condition</description>
    <arm_group_label>PartA, Treatment-2</arm_group_label>
    <other_name>PartA, Test(CKD-387 10/500mg)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part B, Reference (D635 10/500mg, Astrazeneca)</intervention_name>
    <description>Once a day. Under fed condition</description>
    <arm_group_label>PartB, Treatment-1</arm_group_label>
    <other_name>PartB, Test(CKD-387 10/500mg)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part B, Reference (D635 10/500mg, Astrazeneca)</intervention_name>
    <description>Once a day. Under fed condition</description>
    <arm_group_label>PartB, Treatment-2</arm_group_label>
    <other_name>PartB, Test(CKD-387 10/500mg)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult older than 19 years and less than 45 years at the time of screening.&#xD;
&#xD;
          2. BMI 18.5~29.9 kg/m2 and body weight more than 50kg.&#xD;
&#xD;
          3. Subjects who have consented to the use of appropriate double- pregnancy contraceptive&#xD;
             methods up to one months after the last investigational product and not to provide&#xD;
             sperm for men.&#xD;
&#xD;
          4. Subjects who sign on an informed consent form willingly.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who have a clinically significant disease or medical history such as&#xD;
             respiratory, hepatic, kidneys, blood, gastrointestinal, endocrine, immune system,&#xD;
             skin, nervous and mental disease.&#xD;
&#xD;
          2. Subjects who have acute disease within 28 days prior to the first administration.&#xD;
&#xD;
          3. Subjects who have history that may affect the ADME.&#xD;
&#xD;
          4. Subjects who have medical history or medical abuse history of hypersensitivity from&#xD;
             SGLT inhibitors or Biguanides including Metformin or other medications(Aspirin,&#xD;
             Antibiotics etc.).&#xD;
&#xD;
          5. Subjects who have clinically significant chronic disease.&#xD;
&#xD;
          6. Subjects with genetic problems such as galactose intolerance, Lapp lactase deficiency&#xD;
             or glucose-galactose mal-absorption.&#xD;
&#xD;
          7. Subjects whose laboratory test result are same as below;&#xD;
&#xD;
               -  AST,ALT &gt; UNL(Upper Normal Limit)x3&#xD;
&#xD;
               -  Fasting glucose level out of 70-125mg/dl&#xD;
&#xD;
               -  Creatinine clearance is lower than 80mL/min which is calcuated by Cockcroft-Gault&#xD;
                  formulation.&#xD;
&#xD;
               -  QT&gt;450msec&#xD;
&#xD;
               -  Positive urine hCG(female).&#xD;
&#xD;
          8. Subjects whoes blood pressure exceeds out of normal range as below at screening.&#xD;
&#xD;
               -  SBP : over 100mmHg, under 160mmHg&#xD;
&#xD;
               -  DBP : over 60mmHg, under 100mmHg&#xD;
&#xD;
          9. Subjects who have been found to be positive in serological tests(HBs antigen, HCV&#xD;
             antibody and HIV antibody).&#xD;
&#xD;
         10. Subjects who took ETC(Ethical Drug), oriental medicine within 2 weeks prior to the&#xD;
             first administration of investigational products.&#xD;
&#xD;
         11. Subjects who took OTC(Over-the-counter Drug, including korean galenical drug) within&#xD;
             10 days prior to the first administration of investigational products.&#xD;
&#xD;
         12. Subjects who have allergic disease which has clinical significance(But, light allergic&#xD;
             rhinitis and ligth allergic dermatitis which do not need medication is exceptional).&#xD;
&#xD;
         13. Subjects who can not eat standard meals provided by the institution.&#xD;
&#xD;
         14. Subjects who donated whole blood within 60 days, donated the blood components within&#xD;
             20 days prior to the first administration of investigational products.&#xD;
&#xD;
         15. Subjects who received blood transfusion within 30 days prior to the first&#xD;
             administration of investigational products.&#xD;
&#xD;
         16. Subjects who were participated in the other clinical trial within 90 days prior to the&#xD;
             first administration of investigational products.&#xD;
&#xD;
         17. Subjects who took medication for the induction and inhibition of metabolizing enzymes&#xD;
             such as barbiturate drugs within 6months prior to the first administration of&#xD;
             investigational products.&#xD;
&#xD;
         18. Subjects who have had abnormal diets that can affect the ADME of the drug within 30&#xD;
             days prior to the first administration of investigational products. (Ingestion of&#xD;
             grapefruit juice&gt;1L/day or Caffein&gt;5Cups/day).&#xD;
&#xD;
         19. Subjects who have took regular alcohol(alcohol&gt;30g/day) prior to the first&#xD;
             administration of investigational products.&#xD;
&#xD;
         20. Subjects who smoked more than 10 cigarettes per day prior 3months to the first&#xD;
             administration of investigational products or cannot discontinue smoking during the&#xD;
             clinical trial.&#xD;
&#xD;
         21. Subjects who is determined unsuitable to participate in this clinical trial by the&#xD;
             investigator.&#xD;
&#xD;
         22. Lactating Women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ji-Young Park, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Anam Hospital / Seoul, Seongbuk-Gu, South Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seongbuk-Gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 6, 2019</study_first_submitted>
  <study_first_submitted_qc>November 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2019</study_first_posted>
  <last_update_submitted>November 6, 2019</last_update_submitted>
  <last_update_submitted_qc>November 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type2 Diabetes Mellitus</keyword>
  <keyword>CKD-387</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

